{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T16:18:10Z","timestamp":1780935490979,"version":"3.54.1"},"reference-count":34,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2020,10,14]],"date-time":"2020-10-14T00:00:00Z","timestamp":1602633600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0240374","type":"journal-article","created":{"date-parts":[[2020,10,14]],"date-time":"2020-10-14T18:22:55Z","timestamp":1602699775000},"page":"e0240374","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":25,"title":["Tolerability of oral itraconazole and voriconazole for the treatment of chronic pulmonary aspergillosis: A systematic review and meta-analysis"],"prefix":"10.1371","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1289-0111","authenticated-orcid":true,"given":"Ronald","family":"Olum","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5852-9674","authenticated-orcid":true,"given":"Joseph Baruch","family":"Baluku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0738-8234","authenticated-orcid":true,"given":"Andrew","family":"Kazibwe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Russell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4515-8517","authenticated-orcid":true,"given":"Felix","family":"Bongomin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2020,10,14]]},"reference":[{"issue":"Supplement_3","key":"pone.0240374.ref001","doi-asserted-by":"crossref","first-page":"S265","DOI":"10.1086\/376526","article-title":"Chronic cavitary and fibrosing pulmonary and pleural aspergillosis: case series, proposed nomenclature change, and review","volume":"37","author":"DW Denning","year":"2003","journal-title":"Clin Infect Dis"},{"issue":"4","key":"pone.0240374.ref002","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1183\/09031936.00054810","article-title":"Underlying conditions in chronic pulmonary aspergillosis including simple aspergilloma","volume":"37","author":"NL Smith","year":"2011","journal-title":"Eur Respir J"},{"issue":"1","key":"pone.0240374.ref003","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1183\/13993003.00583-2015","article-title":"Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management","volume":"47","author":"DW Denning","year":"2016","journal-title":"Eur Respir J"},{"issue":"4","key":"pone.0240374.ref004","doi-asserted-by":"crossref","first-page":"e0193732","DOI":"10.1371\/journal.pone.0193732","article-title":"Twelve-month clinical outcomes of 206 patients with chronic pulmonary aspergillosis","volume":"13","author":"F Bongomin","year":"2018","journal-title":"PLoS One"},{"issue":"6","key":"pone.0240374.ref005","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1093\/cid\/cit411","article-title":"Long-term antifungal treatment improves health status in patients with chronic pulmonary aspergillosis: a longitudinal analysis","volume":"57","author":"K Al-Shair","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"3","key":"pone.0240374.ref006","article-title":"Treatment of Aspergillosis","volume":"4","author":"JD Jenks","year":"2018","journal-title":"Journal of fungi (Basel, Switzerland)"},{"issue":"5","key":"pone.0240374.ref007","first-page":"835","article-title":"Selection of Oral Antifungals for Initial Maintenance Therapy in Chronic Pulmonary Aspergillosis: A Longitudinal Analysis","volume":"70","author":"M Tashiro","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"4","key":"pone.0240374.ref008","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1007\/s12281-017-0304-7","article-title":"The Management of Chronic Pulmonary Aspergillosis: The UK National Aspergillosis Centre Approach","volume":"11","author":"F Maghrabi","year":"2017","journal-title":"Current fungal infection reports"},{"issue":"2","key":"pone.0240374.ref009","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1159\/000489474","article-title":"Treatment of Chronic Pulmonary Aspergillosis: Current Standards and Future Perspectives","volume":"96","author":"A Alastruey-Izquierdo","year":"2018","journal-title":"Respiration; international review of thoracic diseases"},{"issue":"2","key":"pone.0240374.ref010","article-title":"Chronic Pulmonary Aspergillosis: Notes for a Clinician in a Resource-Limited Setting Where There Is No Mycologist","volume":"6","author":"F Bongomin","year":"2020","journal-title":"Journal of fungi (Basel, Switzerland)"},{"issue":"5","key":"pone.0240374.ref011","doi-asserted-by":"crossref","first-page":"e133","DOI":"10.1016\/j.jinf.2005.08.022","article-title":"The efficacy and tolerability of voriconazole in the treatment of chronic cavitary pulmonary aspergillosis","volume":"52","author":"LR Jain","year":"2006","journal-title":"J Infect"},{"issue":"6","key":"pone.0240374.ref012","doi-asserted-by":"crossref","first-page":"527.e17","DOI":"10.1016\/j.amjmed.2005.11.028","article-title":"Voriconazole treatment for subacute invasive and chronic pulmonary aspergillosis","volume":"119","author":"H Sambatakou","year":"2006","journal-title":"The American journal of medicine"},{"key":"pone.0240374.ref013","first-page":"1","article-title":"An overview of the available treatments for chronic cavitary pulmonary aspergillosis","volume":"2020","author":"IS Sehgal","journal-title":"Expert Rev Respir Med"},{"issue":"9","key":"pone.0240374.ref014","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1093\/jac\/dkr233","article-title":"Peripheral neuropathy in patients on long-term triazole antifungal therapy","volume":"66","author":"CG Baxter","year":"2011","journal-title":"The Journal of antimicrobial chemotherapy"},{"issue":"7","key":"pone.0240374.ref015","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"D Moher","year":"2009","journal-title":"PLoS Med"},{"issue":"1","key":"pone.0240374.ref016","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/2049-3258-72-39","article-title":"Metaprop: a Stata command to perform meta-analysis of binomial data","volume":"72","author":"VN Nyaga","year":"2014","journal-title":"Arch Public Health"},{"issue":"3","key":"pone.0240374.ref017","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/myc.12885","article-title":"Isavuconazole and voriconazole for the treatment of chronic pulmonary aspergillosis: A retrospective comparison of rates of adverse events","volume":"62","author":"F Bongomin","year":"2019","journal-title":"Mycoses"},{"issue":"3","key":"pone.0240374.ref018","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s15010-014-0711-4","article-title":"Treatment of chronic pulmonary aspergillosis with voriconazole: review of a case series","volume":"43","author":"G Cucchetto","year":"2015","journal-title":"Infection"},{"issue":"5","key":"pone.0240374.ref019","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/myc.12075","article-title":"Itraconazole in chronic cavitary pulmonary aspergillosis: a randomised controlled trial and systematic review of literature","volume":"56","author":"R Agarwal","year":"2013","journal-title":"Mycoses"},{"issue":"11","key":"pone.0240374.ref020","doi-asserted-by":"crossref","first-page":"3231","DOI":"10.1007\/s10096-012-1690-y","article-title":"Voriconazole for chronic pulmonary aspergillosis: a prospective multicenter trial","volume":"31","author":"J Cadranel","year":"2012","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"6","key":"pone.0240374.ref021","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s15010-012-0322-x","article-title":"Efficacy and safety of voriconazole in the treatment of chronic pulmonary aspergillosis: experience in Japan","volume":"40","author":"T Saito","year":"2012","journal-title":"Infection"},{"issue":"5","key":"pone.0240374.ref022","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1378\/chest.06-2441","article-title":"Treatment of chronic pulmonary aspergillosis by voriconazole in nonimmunocompromised patients","volume":"131","author":"J Camuset","year":"2007","journal-title":"Chest"},{"issue":"2","key":"pone.0240374.ref023","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01062-2016","article-title":"Predictors of mortality in chronic pulmonary aspergillosis","volume":"49","author":"D Lowes","year":"2017","journal-title":"Eur Respir J"},{"key":"pone.0240374.ref024","article-title":"Intravenous therapy for chronic pulmonary aspergillosis: A systematic review and meta-analysis","author":"F Bongomin","year":"2020","journal-title":"Mycoses"},{"issue":"12","key":"pone.0240374.ref025","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1086\/657306","article-title":"Efficacy and safety of posaconazole for chronic pulmonary aspergillosis","volume":"51","author":"TW Felton","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"2","key":"pone.0240374.ref026","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.ijantimicag.2018.06.001","article-title":"Assessment of posaconazole salvage therapy in chronic pulmonary aspergillosis using predefined response criteria","volume":"52","author":"I Rodriguez-Goncer","year":"2018","journal-title":"Int J Antimicrob Agents"},{"issue":"8","key":"pone.0240374.ref027","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1086\/424662","article-title":"Adverse reactions to voriconazole","volume":"39","author":"AE Boyd","year":"2004","journal-title":"Clin Infect Dis"},{"issue":"2","key":"pone.0240374.ref028","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3121\/cmr.2008.806","article-title":"Voriconazole-induced photosensitivity","volume":"6","author":"AN Malani","year":"2008","journal-title":"Clin Med Res"},{"issue":"5","key":"pone.0240374.ref029","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1086\/324620","article-title":"Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis","volume":"34","author":"DW Denning","year":"2002","journal-title":"Clin Infect Dis"},{"issue":"3","key":"pone.0240374.ref030","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1001\/archdermatol.2009.362","article-title":"Melanoma associated with long-term voriconazole therapy: a new manifestation of chronic photosensitivity","volume":"146","author":"DD Miller","year":"2010","journal-title":"Arch Dermatol"},{"issue":"2","key":"pone.0240374.ref031","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1167\/iovs.14-15270","article-title":"Voriconazole, an antifungal triazol that causes visual side effects, is an inhibitor of TRPM1 and TRPM3 channels","volume":"56","author":"W-H Xiong","year":"2015","journal-title":"Investigative ophthalmology & visual science"},{"issue":"1","key":"pone.0240374.ref032","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1159\/000359952","article-title":"Effects of multiple doses of voriconazole on the vision of healthy volunteers: a double-blind, placebo-controlled study","volume":"52","author":"E Zrenner","year":"2014","journal-title":"Ophthalmic Res"},{"key":"pone.0240374.ref033","doi-asserted-by":"crossref","first-page":"100015","DOI":"10.1016\/j.clinpr.2020.100015","article-title":"Risk factors for relapse of chronic pulmonary aspergillosis after discontinuation of antifungal therapy","author":"F Bongomin","year":"2020","journal-title":"Clinical Infection in Practice"},{"issue":"1","key":"pone.0240374.ref034","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1128\/CMR.00046-13","article-title":"Tissue penetration of antifungal agents","volume":"27","author":"T Felton","year":"2014","journal-title":"Clin Microbiol Rev"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0240374","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,14]],"date-time":"2020-10-14T18:23:28Z","timestamp":1602699808000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0240374"}},"subtitle":[],"editor":[{"given":"Ahmed","family":"Negida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2020,10,14]]},"references-count":34,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2020,10,14]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0240374","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,14]]}}}